Combination treatment for solid tumors that stopped responding to prior therapy
Part of Cancer clinical trials.
This trial tests a new combination of two drugs (PIN plus an anti-PD1 immunotherapy) for people with advanced solid tumors that either did not respond to standard treatment or have tumor types known to have low response to immunotherapy, like liver cancer. The goal is to see if this combination can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced or metastatic solid tumor that has not responded to at least one prior treatment, or there is no standard first-line therapy for your cancer type.
- Your tumor has shown resistance, no response, or low response to prior anti-PD-1/PD-L1 immunotherapy (for example, liver cancer).
- You have at least one tumor that can be measured on scans and one tumor that can be injected directly (at least 1 cm wide).
- You are willing to have a new tumor biopsy during the study.
- Your kidney, liver, and blood cell counts are within acceptable ranges, and your heart function is normal.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment combining a drug called PIN with an immunotherapy (anti-PD1) for people with advanced liver cancer (HCC) that has stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or control the disease.
This trial tests a new combination of two medicines, pin and sintilimab, for people with advanced colorectal cancer that has spread to the liver and has already been treated with at least two standard therapies. The study aims to see if injecting the medicine directly into the liver tumor, combined with immunotherapy through a vein, can shrink tumors and help patients live longer.
This trial tests a combination of two drugs (5-Azacitidine and a PD-1/PD-L1 inhibitor) for people whose solid tumors stopped responding to standard PD-1/PD-L1 immunotherapy alone. The goal is to see if this new combination can help shrink the tumor or slow its growth.
This study tests a new drug (BM230) combined with a PD-1 inhibitor (a type of immunotherapy) for advanced cancers that have HER2. It aims to see if the combination is safe and effective in treating tumors that have stopped responding to standard treatments.
This study tests a combination of two investigational drugs (Simmitinib and SG001) in people with advanced solid tumors that have not responded to standard treatment. The goal is to see if this combination can shrink tumors or slow their growth, and to find the best dose for further studies.
This trial tests a combination of two drugs: peginterferon α-2b (an immune-boosting drug) and an anti-PD-1 antibody (a type of immunotherapy that helps your immune system fight cancer). They hope the combo might work better for people with advanced solid tumors that haven't responded to other treatments.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.